Navigation Links
NuVasive Announces Web Cast and Conference Call of Second Quarter 2008 Results
Date:7/14/2008

SAN DIEGO, July 14 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today details relating to its second quarter 2008 earnings announcement, which will take place on Thursday, July 24, 2008 after the close of the market.

NuVasive will hold a conference call on Thursday, July 24, 2008 at 5:30 p.m. ET / 2:30 p.m. PT to discuss the results. The dial-in numbers are 1-877-407-4018 for domestic callers and 1-201-689-8471 for international. A live Web cast of the conference call will be available online from the investor relations page of the Company's corporate Web site at http://www.nuvasive.com.

After the live Web cast, the call will remain available on NuVasive's Web site, http://www.nuvasive.com, through August 24, 2008. In addition, a telephonic replay of the call will be available until August 14, 2008. The replay dial-in numbers are 1-877-660-6853 for domestic callers and 1-201-612-7415 for international callers. Please use account number 3055 and conference ID number 289122.

About NuVasive

NuVasive is a medical device company focused on the design, development and marketing of products for the surgical treatment of spine disorders. The Company's product portfolio is focused on applications in the over $4.2 billion U.S. spine fusion market. The Company's current principal product offering includes a minimally disruptive surgical platform called Maximum Access Surgery, or MAS(R), as well as a growing offering of cervical and motion preservation products.

The MAS platform offers advantages for both patients and surgeons such as reduced surgery and hospitalization time and faster recovery. MAS combines three categories of current product offerings: NeuroVision(R) a proprietary software-driven nerve avoidance system; MaXcess(R) a unique split-blade design retraction system; and specialized implants, like SpheRx(R) and CoRoent(R), that collectively minimize soft tissue disruption during spine surgery while allowing maximum visualization and surgical reproducibility. NuVasive's product offering is also focused on cervical internal fixation products and its R&D pipeline emphasizes both MAS and motion preservation.

NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to: the uncertain process of seeking regulatory approval or clearance for NuVasive's products or devices, including risks that such process could be significantly delayed; the possibility that the FDA may require significant changes to NuVasive's products or clinical studies; the risk that products may not perform as intended and may therefore not achieve commercial success; the risk that competitors may develop superior products or may have a greater market position enabling more successful commercialization; the risk that additional clinical data may call into question the benefits of NuVasive's products to patients, hospitals and surgeons; and other risks and uncertainties more fully described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at http://www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

Contact: Investors:

Kevin C. O'Boyle Nick Laudico/Zack Kubow

EVP & Chief Financial Officer The Ruth Group

NuVasive, Inc. 646-536-7030/7020

858-909-1800 nlaudico@theruthgroup.com

investorrelations@nuvasive.com zkubow@theruthgroup.com

Media:

Jason Rando

The Ruth Group

646-536-7025

jrando@theruthgroup.com


'/>"/>
SOURCE NuVasive, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
2. NuVasive to Host Investor Reception on September 11, 2007
3. NuVasive Announces Webcast and Conference Call of Fourth Quarter and Full Year 2007 Results
4. NuVasive to Present at Canaccord Adams Small-Cap Orthopedics Conference
5. NuVasive to Present at Lehman Brothers Eleventh Annual Global Healthcare Conference
6. NuVasive Signs Definitive Agreement to Acquire Osteocel Biologics Business from Osiris Therapeutics
7. NuVasive to Present at William Blair 28th Annual Growth Stock Conference
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... and SAN FRANCISCO , ... privately-held regenerative medicine company, and Beyond Type 1, a ... type 1 diabetes, today announced a grant from Beyond ... functional cure for type 1 and other insulin-requiring diabetes.  ... has been developing innovative stem cell-derived cell replacement therapies ...
(Date:2/22/2017)... , Feb. 22, 2017  PrimeVax Immuno-Oncology, Inc. ... be presenting at the Annual Biocom Global Life Science ... 2, at 11:15 AM, at the Torrey Pines Lodge, ... to the organizers at Biocom who have chosen our ... symposium of biotechnology companies, investors, and clinical researchers," said ...
(Date:2/22/2017)... ... February 22, 2017 , ... LabRoots , the leading provider ... the world, is pleased to announce the launch of a new scholarship for young ... fields. , This merit-based scholarship is open to all high school seniors, 17 years ...
(Date:2/22/2017)... ... February 22, 2017 , ... Pharma and ... Perkins as European director. Operating from Pennside’s Zurich headquarters, Pennside Partners, GmbH, Mr. ... joins Pennside after more than a decade with leading market research firm, GfK. ...
Breaking Biology Technology:
(Date:1/26/2017)... , Jan. 26, 2017  Acuity Market ... for Biometrics and Digital Identity".  Acuity characterizes 2017 ... identity when increased adoption reflects a new understanding ... "Biometrics and digital identity are often ... Maxine Most , Principal of Acuity Market ...
(Date:1/24/2017)... YORK , Jan. 24, 2017 ... study of the laboratory use of nuclear magnetic ... 363 experienced end-users and profiled current practices, developments, ... years, as well as growth and opportunities. These ... Instrument suppliers, NMR instruments, needs and innovation requirements, ...
(Date:1/23/2017)... latest mobile market research from Acuity Market Intelligence reveals ... average price of a biometric smartphone decreased from $849 ... are now 120 sub-$150 models on the market at ... a year ago at an average price of $127. ... Acuity Market Intelligence Principal, "Biometric Smartphones are a global ...
Breaking Biology News(10 mins):